-
-
Academic research institutions continue to cope with challenging economic times, looking for ways to cut costs and improve efficiencies. IRB directors can make a good case that one of the best ways to do both is to move to an electronic data and IRB review system.
-
The drive to improve participation in cancer clinical trials has led one cancer center to try a novel approach, using humor and a game show format to educate people about participation in research.
-
There are many biomedical and socio-behavioral studies that include questions about childhood sexual abuse since this is a major risk factor for a variety of illnesses.
-
Some IRBs are beginning to change how they view the risks of asking sensitive questions of subjects in social-behavioral research studies.
-
As the lingering pain of the recession continues to hamper state budgets, the prospect of furloughs may easily be in many IRBs' futures.
-
Acute stroke trials pose unique ethical challenges to researchers, and by extension to IRBs. Stroke interventions are extremely time-sensitive, meaning that decisions about treatment and research participation often must be made quickly.
-
A third inhaled corticosteroid and long-acting beta-agonist combination has been approved by the FDA, joining currently marked combinations fluticasone/salmeterol (Advair Diskus®) and budesonide/formoterol (Symbicort®). Mometasone furoate and formoterol fumarate is marketed by Schering as Dulera®
-
Dietary pattern analysis of elderly subjects followed over at least 4 years showed lower risk for developing Alzheimer's disease when there was higher intake of nuts, fish, tomatoes, poultry, salad dressing, cruciferous vegetables, fruits, and dark and green leafy vegetables, along with lower intake of high-fat diary products, red meat, organ meat, and butter.
-
Although there are few studies that specifically look at the elderly, this review provides useful information on the diagnosis and treatment of acute exacerbation of COPD and chronic bronchitis.